Vivalto Partners’ Equity Investment in Laboratoires Delbert LPA-CGR avocats advised Laboratoires Delbert on Vivalto Partners’ acquisition of a stake in its business. Fieldfisher advised Vivalto Partners on the investment. Laboratoires Delbert is a Parisian laboratory founded in 2002 and acquired by Marc Childs and Thierry Hoffmann in 2013. The laboratory specialises in the acquisition and maintenance of major and essential drugs as identified by the World Health Organisation. Laboratoires Delbert is best known for its expertise in securing production chains, limiting supply disruption risk and acting as a reference partner for regulatory authorities and large pharmaceutical firms. Founded in 2021 by Vivalto Santé clinic group founder Daniel Caille, Vivalto Partners is an investment management firm active in the French healthcare space. Its investment in Laboratoires Delbert will enable the firm to advance its progress in a new phase of development, supporting its rapid international growth and helping to address drug shortages. Laboratoires Delbert has declared its goal of being recognised as a mission-driven company in the near future, as has Vivalto Santé. LPA-CGR avocats advised Laboratoires Delbert on this secondary LBO with a team comprising partners Raphaël Chantelot and Mathieu Selva-Roudon, as well as associates Maxime Ponsan, Céline Guo and Déborah Théry. ABOUT THE DEAL 84 LAWYER MONTHLY AUGUST 2023
RkJQdWJsaXNoZXIy Mjk3Mzkz